MedWatch

US withdrawal from Iran deal can hit Danish companies

The US's withdrawal from the Joint Plan of Action with Iran and the reimposition of sanctions can impact Danish pharmaceutical companies and medico firms, writes the Danish interest group Dansk Industri. Novo Nordisk, which has invested DKK 500 million (EUR 67 million) in Iran, awaits further developments.

Iranians protested on Friday after US President Trump decided to withdraw from the Joint Comprehensive Plan of Action and reimposed sanctions. Photo: /Ritzau Scanpix/AFP/STR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Her er de vigtigste nyheder fra MedWatch i uge 38

En "digital transformation" i Novo Nordisks F&U-afdeling, som koster 400 medarbejdere jobbet, stjal fokus i uge 38, hvor Zealand Pharma ramte plet i et afgørende fase 3-studie og Coloplast holdt kapitalmarkedsdag. MedWatch giver dig her overblikket over ugens vigtigste begivenheder.

CHMP får ny, tysk formand

Ved sit septembermøde har EU's ekspertkomité på ibrugtagning af nye lægemidler, CHMP, valgt en ny formand for de næste tre år, ny næstformand skal vælges i næste måned.

Related articles